Harmony Biosciences
HRMY
59 hedge funds and large institutions have $998M invested in Harmony Biosciences in 2020 Q4 according to their latest regulatory filings, with 29 funds opening new positions, 13 increasing their positions, 12 reducing their positions, and 14 closing their positions.
107% more first-time investments, than exits
New positions opened: 29 | Existing positions closed: 14
34% more funds holding
Funds holding: 44 → 59 (+15)
6% more capital invested
Capital invested by funds: $941M → $998M (+$57.5M)
4.31% more ownership
Funds ownership: 44.83% → 49.14% (+4.3%)
8% more repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 12
0% more funds holding in top 10
Funds holding in top 10: 5 → 5 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
Ashford Capital Management
Wilmington,
Delaware
|
+$11M |
| 2 |
SPPAM
Summit Partners Public Asset Management
Boston,
Massachusetts
|
+$10.4M |
| 3 |
Janus Henderson Group
London,
|
+$8.86M |
| 4 |
BlackRock
New York
|
+$7.6M |
| 5 |
Massachusetts Financial Services
Boston,
Massachusetts
|
+$7.42M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$45.9M |
| 2 |
Millennium Management
New York
|
-$10.9M |
| 3 |
BBA
Baker Bros. Advisors
New York
|
-$8.88M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$7.75M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$7.1M |
HRMY Hedge Fund Activity: Q4 2020 in Review
59 of the 5,676 institutional investors tracked by Wall St. Rank reported a position in Harmony Biosciences (HRMY) for Q4 2020, worth a combined $998M — up 6.1% from $941M a quarter earlier.
Buyers outnumbered sellers: 29 funds opened new HRMY positions and 14 closed out — a net gain of 15 holders — while 13 added to existing stakes and 12 trimmed.
The largest buyer was Ashford Capital Management, opening a new position worth an estimated $11M. The largest seller was Fidelity Investments, cutting an estimated $45.9M.
- 59 institutional investors held Harmony Biosciences (HRMY) as of Q4 2020, up from 44 in Q3 2020.
- Funds reported $998M of Harmony Biosciences stock for Q4 2020, up 6.1% quarter-over-quarter.
- 29 funds opened new Harmony Biosciences positions in Q4 2020 and 14 closed out, a net change of +15 holders.
- The largest Harmony Biosciences buyer in Q4 2020 was Ashford Capital Management, an estimated $11M added.
- The largest Harmony Biosciences seller in Q4 2020 was Fidelity Investments, an estimated $45.9M sold.
Based on aggregated 13F filings for Q4 2020.